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ABSTRAK
Untuk menangani kasus Avian Influenza A/H5N1 serta mengantisipasi potensi terjadinya pandemi yang 
diakibatkan oleh virus tersebut, Indonesia telah membeli dan mendistribusikan Oseltamivir ke sarana kesehatan 
yang dimiliki pemerintah. Oseltamivir adalah obat antivirus untuk pengobatan infeksi influenza. Surveilans 
penyakit dan penelitian menunjukkan bahwa influenza musiman (A/H1N1, A/H3N2 atau B) mengakibatkan angka 
morbiditas dan mortalitas yang tinggi di Indonesia. Lebih dari 15% pasien dengan penyakit yang menyerupai 
influenza dan penyakit saluran pernapasan akut yang berat, positif terhadap virus influenza. Indonesia saat ini 
membatasi penggunaan oseltamivir untuk penanganan kasus avian influenza A/H5N1 dan antisipasi pandemi 
yang dipicu oleh virus A/H5N1. Kami menjabarkan hal-hal yang mendukung penggunaan oseltamivir dalam 
pengobatan infeksi influenza musiman sehingga para dokter mempunyai pilihan untuk memberikan obat ini. 
Kami berpendapat bahwa manfaat kebijakan ini lebih besar dibandingkan dengan  risiko terjadinya resistensi 
terhadap obat antivirus. Kami merekomendasikan ketersediaan oseltamivir sehingga dapat diberikan pada 
pasien dengan infeksi influenza musiman, terutama bagi mereka yang dirawat di rumah sakit dan  mereka 
yang beresiko tinggi terhadap komplikasi serta hasil pengobatan yang buruk. Secara keseluruhan, diharapkan 
kebijakan ini akan menurunkan angka morbiditas dan mortalitas akibat influenza musiman.
Kata kunci: antivirus, kebijakan, Indonesia, influenza, pengobatan.
ABSTRACT
To manage cases of avian influenza A/H5N1 virus infection and in anticipation of a pandemic triggered 
by this virus, Indonesia purchased and distributed oseltamivir to the government health facilities. Oseltamivir 
is an antiviral drug that was developed for the treatment of influenza infections. Disease surveillance and 
research suggests that seasonal influenza (A/H1N1, A/H3N2 or B) results in considerable morbidity and 
mortality in Indonesia, where over 15% of influenza-like illness and severe acute respiratory illness patients test 
positive for the influenza virus. Indonesia currently limits oseltamivir for the management of avian influenza A/
H5N1cases and in anticipation of a pandemic triggered by the A/H5N1 virus. We present the evidence for the 
use of oseltamivir in the treatment of seasonal influenza infections so that doctors have the option to prescribe 
the drug. We propose that the benefits of this approach will largely outweigh the risk of antiviral resistance. 
We recommend that oseltamivir be available for administration to patients with seasonal influenza infections, 
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especially for those hospitalized and for groups with high risk of complications and adverse outcomes. Overall, 
this will reduce morbidity and mortality of seasonal influenza.
Key words: antiviral, policy, Indonesia, influenza, treatment.
INTRODUCTION
Influenza is perceived as a mild infectious 
disease that could be managed with symptomatic 
medications, vitamins and rest. However, with 
the emergence of the avian influenza H5N1 virus, 
awareness among clinicians about the broader 
spectrum of influenza illness has increased. The 
World Health Organization (WHO) recommends 
the use of oseltamivir and other antivirals for 
seasonal influenza and avian influenza H5N1 
patient management.1 In Indonesia, the Ministry 
of Health rapidly purchased and distributed 
several million doses of oseltamivir to all health 
centers and hospitals, reserving the drug for the 
management of avian influenza H5N1 cases.2 
Yet, with the increasing data about the burden of 
influenza in Indonesia and globally,3-5 the drug also 
has the potential to be used in the management of 
seasonal influenza. As it is undistinguishable from 
acute bacterial respiratory infections, seasonal 
influenza is often treated with symptomatic 
medications or antibiotics.
This paper asks the question: Is it time to 
use antivirals in the management of seasonal 
influenza in Indonesia? We present the supporting 
evidence including findings from Indonesia, 
and discuss common concerns. We describe 
the magnitude of influenza disease burden, the 
groups at risk of complications and adverse 
outcomes, and then discuss the various options 
available for disease control and treatment with 
a specific focus on oseltamivir since it is already 
available in Indonesia. We aim to stimulate 
policy update in Indonesia, and suggest the use of 
antivirals for the clinical management of seasonal 
influenza cases, especially amongst hospitalized 
patients and patients from groups known to be at 
high risk of adverse outcomes.
BURDEN OF SEASONAL INFLUENZA 
INFECTION
Recent studies in South-East Asia show that 
seasonal influenza causes severe disease and has 
similar or even higher disease burden compared 
to temperate countries.6,7 In a multi-country 
study, influenza was associated with 10.6, 
13.4 and 8.3 deaths per 100,000 population in 
Guangzhou (China), Hong Kong and Singapore, 
respectively.8 In Thailand, the average annual 
incidence of influenza pneumonia was greatest 
in children less than 5 years of age (236 per 
100,000) and in those age 75 or older (375 per 
100,000), and influenza pneumonia resulted in 
an estimated annual average of 36,413 hospital 
admissions and 322 in-hospital pneumonia 
deaths.9
In Indonesia, during 2003-2007, influenza 
viruses were identified in 20.1% (4.236/21.030) 
of influenza-like illness (ILI) patients, including 
20.1% (4.015/20.012) of outpatients, and 21.7% 
(221/1.018) of hospitalized patients.3 Influenza 
was also found to contribute to a high proportion 
of hospitalized cases: 6% of those with SARI 
(Severe Acute Respiratory Illness).10 These data 
highlight that the perception of influenza is a mild 
self-limiting disease is misled. Influenza can and 
does lead to severe disease and fatalities, and 
results in decreased productivity and significant 
economic losses. Even though Indonesian data 
on the economic impact of influenza are not 
available, Thailand has estimated that economic 
losses due to influenza amount to 23.4-62.9 
million US dollars each year.11
AT-RISK GROUPS
High risk groups for severe illness and death 
due to influenza infection include infants, persons 
over 65 years of age, pregnant women, immune-
compromised people including transplant 
recipients and patients with HIV, and those with 
chronic illnesses such as diabetes mellitus and 
tuberculosis (TB).12
Infants are generally not able to mount an 
adequate immune response when infected with 
the influenza virus, resulting in prolonged levels 
of viral replication. Clinical symptoms can 
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range from brief episodes of moderate fever13 
to severe complications such as shock, acute 
glomerulonephritis, pericardial effusion, and 
encephalitis.14 It is estimated that about 500 
out of 100,000 children under 4 years would 
require hospitalization due to influenza, whilst 
in children with comorbidities such as asthma 
and immune disorders, the hospitalization 
rate is seven-fold at 3,562/100,000 children.15 
In Thailand, the average annual incidence of 
influenza pneumonia in children less than 5 years 
of age was 236 per 100,000 children.9 Currently, 
rates of infant influenza-related hospitalizations 
and mortality are not known in Indonesia, but 
they likely mirror those found in other South-
East Asian countries such as Thailand.
In pregnant women, decreased cellular 
immunity and changes in lung structure are known 
to increase susceptibility to influenza infection.16 
Pregnant women in their second and third 
trimester have a higher risk for hospitalization 
due to cardiac or respiratory complications 
associated with influenza infection.17 Pregnant 
women with comorbid conditions such as 
chronic cardiac disease, chronic pulmonary 
disease, diabetes mellitus, chronic renal disease, 
malignancies, and immunosuppressive disorders 
are more than three times more likely to be 
hospitalized for respiratory illness during the 
influenza season than women without these 
comorbidity.17
In the elderly, the declining condition of 
the immune system, the deteriorating function 
of respiratory tract cilia, the weakening cough 
reflex, and the presence of comorbid diseases 
contribute to the risk of infection and severe 
illness.18 Complications include pneumonia 
due to secondary bacterial infections with 
Stresptococcus pneumoniae, Staphylococcus 
aureus and Haemophilus influenza.18 Immuno-
compromised persons with HIV/AIDS, solid 
organ or haemopoietic stem-cell transplant, 
hemodialisis, cancer, or steroid treatment are 
known to have severe and prolonged influenza 
infections as the immune systems that play a 
crucial part in virus clearance are altered.19
TB infection is a risk factor for severe 
influenza disease. In 2012, WHO reported that 
Indonesia is a country with high TB burden and 
cases of multiple drug resistant (MDR) TB.20  A 
mathematical analysis has shown a significant 
association between tuberculosis and influenza 
mortality during the 1918 A/H1N1 pandemic21 
and in lower rates during the subsequent A/H2N2 
pandemic in 1957 and A/H3N2 pandemic in 
1968.22 However, data describing this association 
are not available in Indonesia.
OPTIONS FOR DISEASE CONTROL
There are a number of options for influenza 
case management and disease control. This 
includes non-pharmaceutical interventions such 
as social distancing and hand hygiene measures, 
as well as pharmaceutical interventions such as 
vaccines and antivirals. We present these options 
to highlight that management of influenza 
is feasible through a variety of methods but 
the use of oseltamivir is likely to be the most 
implementable.
NON-PHARMACEUTICAL INTERVENTIONS
Measures such as school closures and 
cancellation of large gatherings, as well as 
hygiene measures such as hand hygiene and 
face masks may impact the course of influenza 
disease outbreaks. In particular, since school 
age students have highest influenza disease 
prevalence compared to other groups3 and have 
high contact rates and viral shedding. Prevention 
of disease transmission in this cohort can be 
used to reduce excess morbidity and mortality in 
other groups.23 The use of facemasks and hand 
hygiene have been found to reduce household 
disease transmission if implemented early 
and intensively.24 However, the proportion 
of cases averted by these social distancing 
measures remains uncertain.23 Furthermore, 
these population-based interventions may 
minimize disease spread but would not limit the 
severity of illness or outcome for individuals 
ultimately infected by the virus. Therefore, non-
pharmaceutical interventions cannot stand alone 
as disease control measures against influenza.
PHARMACEUTICAL INTERVENTIONS
The two key pharmaceutical interventions 
available for case management and public health 
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disease control of influenza are vaccination and 
antiviral administration.
Vaccination
Increased vaccination coverage in the 
community is correlated with a lower incidence 
of influenza.25 In children, vaccination is 
recommended starting at 6 months of age.13 
Although the efficacy of vaccines in the elderly 
and the immune-compromised is lower than 
the young and healthy adult populations,18 
vaccination is still recommended to reduce 
their risk of serious complications and adverse 
outcomes. Undoubtedly, influenza disease trends 
and burden in Indonesia and other countries 
demonstrates the importance of vaccination as a 
public health disease control measure. However, 
introduction and funding of vaccination requires 
long term planning and assurance that the 
immunization program will reach its target 
audience cost-effectively. Currently, Indonesia 
recommends that hajj pilgrims receive influenza 
vaccine but this program is not funded. To 
develop and implement the policy that expands 
this recommendation to broader risk groups 
and/or funds the vaccination in Indonesia is 
likely to be a protracted process requiring high 
level political commitment. In the interim, the 
availability of antiviral drugs offers an attractive 
alternative to reducing the morbidity and 
mortality associated with influenza.
Antivirals
Anti-influenza drugs include the M2 channel 
blockers, amantadine and rimantadine, and the 
neuraminidase enzyme inhibitors, zanamivir and 
oseltamivir. These drugs interfere with several 
stages in the viral replication cycle: entry, viral 
assembly virus, or release.26 Due to the high 
levels of resistance to M2 channel blockers,26 
they will not be discussed further here.
Zanamivir and oseltamivir are analogues of 
sialic acid that can inhibit this enzyme for viral 
particle release, thereby inhibiting replication 
of both influenza A and B viruses.27 Oseltamivir 
is taken orally, while zanamivir is administered 
by oral inhalation. Zanamivir may cause 
spasms in some patients and may require the 
use of a bronchodilator.28 Since oseltamivir is 
already available in Indonesia, the focus below 
is regarding its utility for seasonal influenza 
treatment. 
Oseltamivir is reported to be most effective 
if given within 48 hours of symptom onset,14 
but it is still beneficial even when given after 
48 hours.28-31 Parameters commonly used to 
demonstrate the efficacy of oseltamivir include: 
duration of illness, fever, length of time that the 
virus is detectable in the respiratory tract, length 
of time needed to return to normal activities, 
duration of treatment, clinical severity, and the 
ability to prevent complications such as otitis 
media, pneumonia, and death.14,29-31 A study in 
Thailand reported that oseltamivir is associated 
with survival in hospitalized human influenza 
pneumonia patients.32
Various studies have been conducted in 
children, adults, and groups of high risk patients. 
A study in 1-12 year old children with influenza 
showed that the duration of illness was shorter in 
patients treated with oseltamivir within 48 hours 
than those not treated (4.2 vs. 5.7 days), the time 
required to return to daily activities was reduced 
by 45 hours, and the incidence of otitis media 
decreased by 40%, thus, automatically reducing 
the use of antibiotics.14 As similar findings are 
reported, oseltamivir is also recommended in 
infants.33
Currently, there is a paucity of data on 
the use of oseltamivir in pregnant women. 
Administration of oseltamivir to hospitalized 
pregnant women infected with the pandemic A/
H1N1pdm09 virus in the UK reduced intensive 
care admissions by 84%.34
Studies in patients with chronic lung or heart 
disease showed that oseltamivir significantly 
reduced the duration of  symptoms by 36.8% 
(p=0.048), duration of fever by 45.2% (p<0.001), 
severity by 43.1% (p<0.001), complications 
by 45% (p<0.001) and antibiotic use by 69% 
(p=0.02).35 The use of oseltamivir in geriatric 
patients demonstrated lower incidence of 
serious complications, less antibiotic use, lower 
hospitalization and mortality rates in those 
treated within 48 hours.29,36
The effectiveness of oseltamivir in healthy 
adults has recently come into question as a 
Cochrane review showed that oseltamivir 
significantly reduces the time to first alleviation 
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of symptoms by 21 hours in influenza patients 
receiving oseltamivir compared to placebo, but 
that the effect of oseltamivir on complications 
and viral transmission could not be credibly 
assessed as available data lacked sufficient 
detail.37 This does warrant further investigation 
globally but one must acknowledge that 
answering such questions may take a long 
time. Further, the finding relates specifically to 
health adults rather than groups at high risk of 
complications and severe illness. Despite the 
Cochrane review, a recent report using country-
level data from forty-two WHO Member States 
from July 2009 to August 2010 demonstrated 
evidence of a protective relationship between 
antiviral drug supply and influenza mortality38 
and the Cochrane review  did not impact WHO’s 
recommendations on oseltamivir usage for the 
management of Influenza (Table 1).
are inadequate to kill the virus prompt the virus 
to mutate in order to survive.
For influenza B and influenza A/H3N2, 
oseltamivir resistance is not as widely reported 
in literature or from routine surveillance systems. 
The only reports were from a study in patients 
with cancer from 2002-2008 where resistance 
to influenza B and A/H3N2 was identified,41 and 
a study in Japan in 2002-2003 that identified 
influenza A/H3N2 resistance in 9 of 50 (18%) 
children who had been treated by too a low dose 
of oseltamivir.38
Oseltamivir resistance among influenza A/
H1N1 viruses is more frequently reported. The 
first report was from a 2000-2001 study in Japan 
where the percentage of resistance in children 
treated with oseltamivir was 16% (7/43).42 
However, the percentage of resistant viruses 
from routine surveillance from 1996-2007 was 
very low.43 Resistance was widespread starting 
in 2007 in several countries in Europe, where 
oseltamivir was rarely used (0-68%)44, in 2007-
2008 in the US (10.9%)45 and in 2008-2009 in 
Japan (99.7%).46 In Indonesia, where oseltamivir 
is rarely used, resistance rates of 13% were found 
in isolates tested in 2007-2008.47
So far, there is no evidence that suggests 
resistance is brought about by the widespread 
but appropriate use of antivirals.48 For example, 
the over-the-counter prescription of oseltamivir 
in New Zealand did not trigger higher resistance 
rates.49 Interestingly, the resistant A/H1N1 
viruses are no longer circulating in most parts 
of the world, as they have been replaced 
by A/H1N1pdm09, which highlights the 
dynamic nature of influenza viruses despite the 
pharmaceutical interventions applied.50,51
A commonly cited argument against the 
use of oseltamivir in Indonesia is the possible 
emergence of a resistant A/H5N1 influenza virus, 
as a result of re-assortment of the virus with 
resistant seasonal influenza viruses. In theory, 
this re-assortment is possible but the probability 
is very low as it requires the same person to be 
infected with the two viruses at the same time. 
Such co-infections have never been reported in 
the literature. Therefore, this remote possibility 
does not seem to warrant withholding antivirals 
from seasonal influenza patients.
Table 1. World Health Organization guideline for the 
pharmaceutical management of Influenza39
Population
Pandemic influenza A (H1N1) 
2009 and other seasonal 
influenza viruses
Uncomplicated clinical presentation
Patients in higher risk 
groups
Treat with oseltamivir or 
zanamivir as soon as possible
Severe or progressive clinical presentation
All patients (including 
children and 
adolescents)
Treat with oseltamivir as 
soon as possible (zanamivir 
should be used if oseltamivir 
unavailable)
Patients with severe 
immunosuppression
Treat with oseltamivir as soon 
as possible. Consider higher 
doses and longer duration of 
treatment
RESISTANCE TO OSELTAMIVIR
A common concern in using oseltamivir in 
the treatment of influenza is antiviral resistance. 
The cause of resistance is mutations that cause 
three-dimensional changes in the neuraminidase 
protein that affects the ability of the drug 
to bind to it.40 Mutation is inherent to the 
influenza virus because of the absence of repair 
mechanism during RNA replication, which is 
then compounded by environmental factors, 
such as the use of antiviral drugs or the immune 
status of the patient. Drug concentrations that 
Vol 46 • Number 1 • January 2014         Managing seasonal influenza: Oseltamivir treatment policy in Indonesia
63
ANTIVIRAL POLICY
Many developed countries use oseltamivir 
for the treatment and prophylaxis for seasonal 
influenza. Since 2007, New Zealand provides 
oseltamivir to patients meeting a clinical case 
definition for influenza at pharmacies without 
prescription.49 One rationale for this is to 
familiarize clinicians with the use of oseltamivir 
for the management of influenza infections in 
anticipation of an influenza pandemic during 
which clinicians are encouraged to prescribe 
antivirals. In England, the Netherlands and 
Australia, oseltamivir is prescribed to patients 
with influenza symptoms that belong to high-risk 
groups for complications.52 In the United States 
and Japan, oseltamivir is prescribed to influenza-
confirmed patients.
Tropical and subtropical countries have 
differing policy. In India, oseltamivir has been 
available under physician’s prescription since 
2009.53 In Singapore, physicians prescribe 
oseltamivir, for immune-compromised patients 
as well as those with hospitalized, laboratory-
confirmed influenza illness presenting within 
48 hour of onset. Singapore also provides 
oseltamivir for prophylaxis of contacts of 
influenza cases in military barracks.54 In 
Malaysia, physicians may prescribe oseltamivir 
to both treat patients and prevent influenza in 
institutional outbreaks.55 Other countries such 
as Laos and Cambodia underutilize oseltamivir, 
where even during the A/H1N1pdm09 pandemic, 
clinicians were hesitant to prescribe it to their 
patients. Despite the varying policies including 
highly liberal use of oseltamivir, resistance rates 
among currently circulating influenza viruses 
remain low.
OSELTAMIVIR APPROACH FOR SEASONAL 
INFLUENZA IN INDONESIA
Based on the disease burden evidence, the 
availability of oseltamivir and the experience of 
oseltamivir usage in other countries, it may be 
the time to develop an approach for the use of 
oseltamivir for seasonal influenza in Indonesia. 
One potential starting point is allowing doctors 
to prescribe and administer oseltamivir to 
influenza-confirmed patients, especially those 
hospitalized and for those groups at high risk of 
adverse outcomes. Oseltamivir use will have two 
key impacts: (1) clinically reduce the severity 
of illness, complications and mortality, and 
(2) epidemiologically reduce the transmission 
of the virus in healthcare settings. We do not 
necessarily advocate for government-funded 
procurement and administration of oseltamivir 
for these groups since this is a decision that needs 
to be based on economic analyses. However, we 
do advocate for a policy which would enable 
doctors to prescribe oseltamivir at patients cost 
if indicated.
Policy development requires a combination 
of evidence and decision-maker commitment. 
The evidence currently available shows that 
influenza disease activity is considerable 
in  Indonesia .  Further  virological  and 
epidemiological surveillance, as well as specific 
research that assesses disease burden and 
cost of influenza to society, may help grip 
decision-maker attention. We recognize that 
our perspective has some limitations. These 
include limited discussion about the cost-benefit 
of oseltamivir in Indonesia and mechanisms to 
operationalize our suggested approach. There 
are currently no studies that assess cost-benefit 
of oseltamivir in Indonesia, but these should be 
considered priority to build the evidence for an 
influenza disease control program. We did not 
elaborate on mechanisms to operationalize our 
recommendation since Government authorities 
and Medical Associations are better places to 
consider these issues in line with regulatory 
requirements.
CONCLUSION
The time has come to think about use of 
oseltamivir for seasonal influenza disease control 
in Indonesia. The rational use of oseltamivir in 
managing influenza patients, especially high 
risk groups may bridge the gap and serve as 
an interim solution to longer term options such 
as vaccination. This paper has discussed the 
available evidence and encourages clinicians, 
public health practitioners as well as decision-
makers to further discuss and develop the relevant 
policies in Indonesia. We call on researchers and 
policy-makers to work together in addressing this 
public health problem. 
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